Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Jérémie Prévost; Romain Gasser; Guillaume Beaudoin-Bussières; Jonathan Richard; Ralf Duerr; Annemarie Laumaea; Sai Priya Anand; Guillaume Goyette; Mehdi Benlarbi; Shilei Ding; Halima Medjahed; Antoine Lewin; Josée Perreault; Tony Tremblay; Gabrielle Gendron-Lepage; Nicolas Gauthier; Marc Carrier; Diane Marcoux; Alain Piché; Myriam Lavoie; Alexandre Benoit; Vilayvong Loungnarath; Gino Brochu; Elie Haddad; Hannah D Stacey; Matthew S Miller; Marc Desforges; Pierre J Talbot; Graham T Gould Maule; Marceline Côté; Christian Therrien; Bouchra Serhir; Renée Bazin; Michel Roger; Andrés Finzi

doi:10.1016/j.xcrm.2020.100126

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Cell Rep Med. 2020 Oct 20;1(7):100126. doi: 10.1016/j.xcrm.2020.100126. Epub 2020 Sep 30.

Authors

Jérémie Prévost^{1

2}, Romain Gasser^{1

2}, Guillaume Beaudoin-Bussières^{1

2}, Jonathan Richard^{1

2}, Ralf Duerr³, Annemarie Laumaea^{1

2}, Sai Priya Anand^{1

4}, Guillaume Goyette¹, Mehdi Benlarbi¹, Shilei Ding¹, Halima Medjahed¹, Antoine Lewin⁵, Josée Perreault⁵, Tony Tremblay⁵, Gabrielle Gendron-Lepage¹, Nicolas Gauthier⁶, Marc Carrier⁷, Diane Marcoux⁸, Alain Piché⁹, Myriam Lavoie¹⁰, Alexandre Benoit¹¹, Vilayvong Loungnarath¹², Gino Brochu¹³, Elie Haddad^{2

14

15}, Hannah D Stacey¹⁶, Matthew S Miller¹⁶, Marc Desforges^{17

14}, Pierre J Talbot¹⁷, Graham T Gould Maule¹⁸, Marceline Côté¹⁸, Christian Therrien¹⁹, Bouchra Serhir¹⁹, Renée Bazin⁵, Michel Roger^{1

2

19}, Andrés Finzi^{1

2

4}

Affiliations

¹ Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
² Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
³ Department of Pathology, New York University School of Medicine, New York, NY 10016, USA.
⁴ Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
⁵ Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada.
⁶ Hôpital Sacré-Cœur de Montréal, Montreal, QC H4J 1C5, Canada.
⁷ Hôpital Cité-de-la-Santé, Laval, QC H7M 3L9, Canada.
⁸ Hôtel-Dieu de Lévis, Lévis, QC G6V 3Z1, Canada.
⁹ Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC J1H 5H4, Canada.
¹⁰ CIUSSS du Saguenay-Lac-Saint-Jean, Hôpital de Chicoutimi, Chicoutimi, QC G7H 5H6, Canada.
¹¹ Hôpital de Verdun, Montreal, QC H4G 2A3, Canada.
¹² CHU de Québec, Hôpital Enfant-Jésus, Quebec, QC G1J 1Z4, Canada.
¹³ CIUSSS de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières, QC G9A 5C5, Canada.
¹⁴ CHU Ste-Justine, Montreal, QC H3T 1C5, Canada.
¹⁵ Département de Pédiatrie, Université de Montréal, Montreal, QC H3T 1C5, Canada.
¹⁶ Micheal G. DeGroote Institute for Infectious Disease Research, Master Immunology Research Centre, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada.
¹⁷ INRS-Institut Armand Frappier, Laval, QC H7V 1B7, Canada.
¹⁸ Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
¹⁹ Laboratoire de Santé Publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.

Abstract

SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.

Keywords: COVID-19; IgG; IgM; RBD; SARS-CoV-2; Spike glycoproteins; coronavirus; cross-reactivity, IgA; neutralization.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

Abstract

Publication types

Grants and funding